Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, a 26-year-old man with folliculitis decalvans unresponsive to standard treatments experienced significant disease clearance after 25 months of systemic photodynamic therapy, marking the first documented use of this therapy for this condition.

In this retrospective study of adolescents with recalcitrant cutaneous lupus, lenalidomide treatment resulted in complete or near resolution of skin symptoms within 6 months, while allowing for a reduction in prednisone dosage.

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

This study observed that class IV diffuse proliferative glomerulonephritis was the most common form of lupus nephritis among the children studied, with remission achieved in a significant portion after treatment.

This study found that trichoscopy can differentiate between dermatomyositis, systemic lupus erythematosus, and systemic sclerosis by identifying distinctive features and may help assess disease activity.

This study found that treating a murine model of systemic lupus erythematosus with early and optimally dosed mesenchymal stem cells effectively suppressed disease severity.

This review discusses the prenatal care guidelines for women with systemic lupus erythematosus and emphasizes the need for disease activity control to reduce maternal and fetal complications; it reports no new results.

This study found that both patients and physicians expressed dissatisfaction with disease control in systemic lupus erythematosus, with patients showing greater dissatisfaction than physicians regarding symptoms.

In this study, the AA genotype of C2 polymorphism was more frequently observed in Chinese patients with systemic lupus erythematosus than controls, indicating it may be a risk factor for the disease.

In this study of Han Chinese women, the mitochondrial DNA N haplogroup was associated with a higher risk of late-onset systemic lupus erythematosus and its specific manifestations, such as skin impairment and neurological disturbances.

This article reviews systemic lupus erythematosus (SLE) and highlights the FDA approval of belimumab, marking the first new SLE treatment in nearly 50 years, but reports no new clinical trial results.

This study produced updated treatment guidelines for severe alopecia areata patients in Korea, highlighting the efficacy of systemic corticosteroids, oral cyclosporine, and Janus kinase inhibitors.

This study found that ringtailed lemurs consuming leucaena in Berenty absorb mimosine, which causes alopecia without affecting body condition or organ toxicity; this may increase infant mortality due to alopecic mothers.

This article is a special issue that reviews current research on the pathogenesis, diagnosis, and treatment of systemic autoimmune diseases, but it does not present new results.

This case report presents a young woman with systemic lupus erythematosus who was found to have CD4+ lymphocytopenia.

This case study suggests that thrombosis was related to anti-phospholipid antibody in a woman with systemic lupus erythematosus, characterized by multiple aseptic bone necroses and arterial blockages.

This study provides a guideline for the safe and effective use of testosterone in women with hypoactive sexual desire disorder, recommending systemic transdermal testosterone for appropriate candidates while highlighting the importance of informed consent and monitoring due to unestablished long-term safety.

In this study, SLE was found to be uncommon among patients with rheumatological complaints in Uganda, with a notable overlap with rheumatoid arthritis and frequent presentation of complications.

This report presents a case of a 17-year-old woman with systemic lupus erythematosus and systemic vasculitis, highlighting the importance of early diagnosis and timely referral for intensive treatment.

This case report presents the first evidence of significant antigen presenting cells around hair follicles in a patient with alopecia due to active systemic lupus erythematosus.

This article rebuts a previous rejection of corticosteroid therapy for alopecia areata, reporting successful treatment in multiple patients with systemic and intralesional steroids and minimal side effects.

This study found that localized skin calcification could be induced in adult rats through dihydrotachysterol treatment combined with topical trauma, offering an experimental model for calcifying scleroderma.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

A woman with lupus and antiphospholipid syndrome had bone damage, showing the need for careful treatment.

This study found that topically administered spironolactone in healthy volunteers resulted in no detectable systemic absorption or changes in related hormone levels over 72 hours, indicating local effect only.

This case study highlights unique management challenges for adolescent females with systemic lupus erythematosus, including medication manipulation due to appearance changes and distinguishing psychological reactions from organic symptoms.

This study found that patients with alopecia areata had higher systemic inflammation markers compared to healthy controls, and these markers were associated with a greater risk of severe disease.

This case report suggests that the mRNA-1273 COVID-19 vaccine may induce systemic lupus erythematosus exacerbation, as observed in a 41-year-old woman who experienced worsened skin symptoms and other complications after vaccination.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.